miRNA profiling in pediatric and young adult Burkitt leukemia and lymphoma
Por:
Schneider B, Redwanz C, Celis-Passini V, Esperanza-Cebollada E, Montesdeoca S, Salaverria I, Planas-Roman S, Conde N, Camós-Guijosa M, Arnau R, Lopez-Guillermo A, Maletzki C, Jou-Munoz C, Erbersdobler A, Shokraie O, Meyer-Bahlburg A, Ballmann M, Mora J, ELENA CAMPO, Classen CF and Cardesa-Salzmann TM
Publicada:
6 feb 2026
Ahead of Print:
1 feb 2026
Resumen:
A translational gap exists in Burkitt leukemia (B-AL) and Burkitt lymphoma (B-Ly) regarding miRNAs associated with clinicopathological features and outcome. The aim of this study was to evaluate differential miRNA expression in a single-center series of pediatric B-AL/B-Ly. Expression profiles of 800 miRNAs in 33 B-AL/B-Ly samples were evaluated using the NanoString nCounter System. Further validation was performed by qPCR utilizing miRNA-specific TaqMan assays. Significantly expressed miRNAs in B-AL/B-Ly were evaluated in silico to identify predicted targeted cancer-related pathways. Analysis of miRNAs deregulated in B-AL/B-Ly compared to normal control lymphoid tissue (NCLT) identified a consistent set of differentially expressed miRNAs, including miR-494-3p, miR-4286, and miR-19a-3p among the higher expressed miRNAs and miR-150-5p, miR-450b-5p, and miR-342-3p among the lower expressed miRNAs in B-AL/B-Ly compared to NCLT (FC > 1.5, p-adj < 0.05). In silico, the main predicted cancer-related signaling pathways targeted by these miRNAs included the MAPK, PI3K-Akt, JAK-STAT, VEGF, TP53, Fas, TGF-beta, and MYC signaling pathways (p-adj < 0.05). B-AL and B-Ly segregated into two major miRNA clusters with sets of significantly overexpressed miRNAs (miR-223-3p, miR-451a, miR-150-5p, miR-144-3p, miR-142-3p, and miR-15a-5p) and lower expressed miRNAs (miR-494-3p, miR-4286, miR-1915-3p, miR-125b-5p, and miR-100-5p) in B-AL compared to B-Ly (FC > 1.5, p-adj < 0.05). Notably, significant downregulation of miR-10a-5p (FC > 1.5, p-adj < 0.05) was observed in the unfavorable outcome group. In summary, new miRNA signatures of relevance in B-AL and B-Ly could be recognized in this study. Studies in larger cohorts are required to further validate these findings.
Filiaciones:
Schneider B:
Institute of Pathology, Rostock University Medical Center, Rostock, Germany
Redwanz C:
Department for Internal Medicine B, Cardiology, University Medicine Greifswald, Greifswald, Germany
Celis-Passini V:
Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain
Esperanza-Cebollada E:
Institut de Recerca Hospital Sant Joan de Déu, Developmental Tumors Biology Group, Leukemia, and Other Pediatric Hemopathies, Pediatric Cancer Center Barcelona, Barcelona, Spain
Montesdeoca S:
Institut de Recerca Hospital Sant Joan de Déu, Developmental Tumors Biology Group, Leukemia, and Other Pediatric Hemopathies, Pediatric Cancer Center Barcelona, Barcelona, Spain
Salaverria I:
Institute of Biomedical Research August Pi Sunyer, Barcelona, University of Barcelona, Barcelona, Spain
Planas-Roman S:
Anatomical Pathology Department, Hospital Sant Joan de Déu, Barcelona, Spain
Conde N:
Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain
Camós-Guijosa M:
Institut de Recerca Hospital Sant Joan de Déu, Developmental Tumors Biology Group, Leukemia, and Other Pediatric Hemopathies, Pediatric Cancer Center Barcelona, Barcelona, Spain
Arnau R:
Anatomical Pathology Department, Hospital Sant Joan de Déu, Barcelona, Spain
Lopez-Guillermo A:
Institute of Biomedical Research August Pi Sunyer, Barcelona, University of Barcelona, Barcelona, Spain
Maletzki C:
Department of Medicine, Clinic III-Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Rostock, Germany
Jou-Munoz C:
Anatomical Pathology Department, Hospital Sant Joan de Déu, Barcelona, Spain
Erbersdobler A:
Institute of Pathology, Rostock University Medical Center, Rostock, Germany
Shokraie O:
Institute of Clinical Chemistry and Laboratory Medicine, Rostock University Medical Center, Rostock, Germany
Pediatrics Department, Pediatric Hematology, Oncology and Palliative Care, Rostock University Medical Center, Rostock, Germany
Meyer-Bahlburg A:
Pediatrics Department, Rostock University Medical Center, Rostock, Germany
Ballmann M:
Pediatrics Department, Rostock University Medical Center, Rostock, Germany
Mora J:
Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain
ELENA CAMPO:
Institute of Biomedical Research August Pi Sunyer, Barcelona, University of Barcelona, Barcelona, Spain
Classen CF:
Pediatrics Department, Pediatric Hematology, Oncology and Palliative Care, Rostock University Medical Center, Rostock, Germany
Cardesa-Salzmann TM:
Pediatrics Department, Pediatric Hematology, Oncology and Palliative Care, Rostock University Medical Center, Rostock, Germany
hybrid
|